ArticleDrug target insights

RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients.

Dablu Lal Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.